<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir an antiviral drug, known to effectively inhibit the 2019-nCOV infection in Vero E6 cells. An open-label non-randomized control study was conducted in the National Clinical Research Centre for Infectious Diseases Shenzhen, China, to assess the effectiveness of Favipiravir in 2019-nCOV treatment. The treatment showed significant assistance in terms of health progress by faster viral clearance and with further research, this can be considered as a standard treatment to combat the SARS-CoV-2 infection (Cai etÂ al., 
 <xref rid="CIT0005" ref-type="bibr">2020</xref>). Further, a randomized controlled trial of combined treatment of Favipiravir and Baloxavir Marboxil also carried out in Zhejiang, China (
 <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=49013" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/showprojen.aspx?proj=49013</ext-link>).
</p>
